Prolongation of the QT interval has been reported for subcutaneous apomorphine, a potent, non‐ergoline dopamine agonist with anti‐parkinsonian benefits comparable to oral carbidopa/levodopa. Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, discusses the results of a randomized study (NCT03187301) assessing the effects of apomorphine sublingual film on QT interval and other cardiac conduction parameters in patients with Parkinson’s disease. Results demonstrated that apomorphine sublingual film did not significantly affect the QT interval in patients with Parkinson’s disease. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.